EP. 14 Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Classifying Vitiligo Severity Beyond Body Surface AreaByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAADAugust 12th 2026
Payer Barriers and Anatomic Urgency in Vitiligo TreatmentByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAADAugust 12th 2026
From Weight Loss to Liver Normalization: A Deep Dive Into the SYNCHRONIZE-1 Trial ResultsByMazen Noureddin, MD, MHScAugust 7th 2026
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASHByMazen Noureddin, MD, MHScAugust 7th 2026
The Primary Care Gap in MASH: Understanding Screening Barriers and the Path to Better DetectionByMazen Noureddin, MD, MHScJuly 31st 2026